Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
03 déc. 2019 08h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it...
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
24 sept. 2019 07h30 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation
23 avr. 2019 08h05 HE
|
ExCellThera
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
12 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
The Alliance for Regenerative Medicine and Informa Pharma Intelligence to Host Regenerative Medicine Advanced Therapy Designation Webinar on June 13, 2018
29 mai 2018 12h09 HE
|
Alliance for Regenerative Medicine
WASHINGTON, D.C., May 29, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM) today announced it will co-host a webinar titled “RMAT Designation – Impact on the Regenerative...
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
23 avr. 2018 08h15 HE
|
Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
05 févr. 2018 11h11 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational...
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
29 janv. 2018 08h45 HE
|
Abeona Therapeutics Inc.
First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...